Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Acorda Therapeutics Shares Surge

A U.S. patent review board on Monday declined to review petitions brought by hedge-fund manager Kyle Bass, who has sought to employ an unusual trading strategy of challenging patents held by pharmaceutical companies and profiting from declines in their stock prices. The U.S. Patent and Trademark Office’s review board ruled against Mr. Bass’s challenge of […]

Read More »

FDA Approves Expanded Use of Promacta for Novartis AG

EAST HANOVER, N.J., Aug. 24, 2015 /PRNewswire/ — Novartis announced today that the US Food and Drug Administration (FDA) has approved an expanded use for Promacta® (eltrombopag) to include children 1 year of age and older with chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. The updated label […]

Read More »

Hedge fund manager Kyle Bass loses challenges to pharma patents

Prominent hedge fund manager Kyle Bass’s campaign to wipe out certain drug patents hit a roadblock on Monday when the U.S. Patent and Trademark Office declined to formally review two patents on Acorda Therapeutics Inc’s flagship multiple sclerosis drug, Ampyra. The decision to reject a review of the patents’ validity comes as the pharmaceutical industry […]

Read More »

China Worries Could Hurt Pharma’s Health

The big worries on growth hanging over the pharmaceuticals industry are poles apart. Pressure on U.S. drug pricing is casting a shadow over the sector’s most lucrative market. But slowing emerging-market growth, notably in China, shouldn’t be ignored. Emerging-market sales for the big pharmaceuticals firms tracked by Sanford C. Bernstein increased by about 5.5%, year […]

Read More »

Lilly, Boehringer diabetes drug cuts heart attack, stroke risk in trial

A new diabetes pill from Eli Lilly and Co and Boehringer Ingelheim cut risk of heart attack, stroke and death in a closely watched study, the first glucose-lowering drug to show such protective results in a large cardiovascular trial, the drugmakers said on Thursday. Besides burnishing the image of the year-old drug, Jardiance, the results […]

Read More »

First trial targeting mutation, not cancer type, gives mixed results

A powerful skin cancer drug may also be effective against lung cancer and other types of malignancies, according to a novel study that focused on a gene mutation seen in many kinds of tumors. This sort of study is “the new wave,” said Dr. Otis Brawley, chief medical officer of the American Cancer Society, who […]

Read More »

Buyer beware: some generic eczema creams pricier than others

Patients who try to save money by getting generic prescriptions for creams and ointments to treat skin conditions like eczema and psoriasis may face sticker shock at the pharmacy, a U.S. study suggests. Researchers compared the average co-payments, or out-of-pocket prices, for several commonly prescribed topical corticosteroids, which have been used for decades to treat […]

Read More »

AbbVie buys special review voucher for $350 million

AbbVie Inc has bought a priority review voucher from United Therapeutics Corp for $350 million that will allow it to accelerate the review process for one of its drugs. United Therapeutics received a rare pediatric disease priority review voucher in March after its drug, Unituxin, was approved by the U.S. Food and Drug Administration to […]

Read More »

Fitch: Even as FDA Approvals Slow, Cancer Treatments Progress in Pharma R&D Pipeline

NEW YORK–(BUSINESS WIRE)–Despite a slight drop in the number of FDA drug approvals during first half 2015 (1H15), treatments for cancer remain an important component of pharmaceutical companies’ R&D pipelines, according to a new Fitch Ratings report. One-third of all drugs approved by the FDA this year were cancer treatments, and positive early data on […]

Read More »

Intarcia’s Diabetes Treatment Clears Key Test

Closely held Intarcia Therapeutics Inc. said its implantable drug-delivery pump proved superior to Merck MRK -0.42 % & Co.’s top-selling drug Januvia in helping diabetes patients control blood sugar in a head-to-head clinical trial. The matchstick-size pump, called ITCA 650, is loaded with a year’s supply of the widely used diabetes drug exenatide and implanted […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!


Ad Right Bottom